Growth capital provider BGF has announced a significant achievement, surpassing £5 billion (€5.8 billion) in capital deployed across more than 650 companies. This milestone arrives fifteen years after the firm was established to address a crucial funding gap for small and mid-sized businesses in the UK. The achievement underscores BGF's consistent strategy and its substantial impact on the nation's growth economy.
A Differentiated Investment Philosophy
BGF operates with a distinct model, providing long-term, flexible capital as a minority equity partner to ambitious businesses. This approach allows entrepreneurs and management teams to retain ownership and control while accessing the resources needed for expansion. Initial investments typically range from £3 million to £30 million for growth-stage companies, with tailored support for earlier-stage ventures.
Fuelling Economic Growth and Returns
The firm's strategy has translated into significant economic impact and robust financial returns over the past fifteen years. BGF-backed companies have collectively generated over £8.2 billion in revenue growth and created more than 35,000 jobs. Since 2016, the firm's exits have delivered an impressive 22.6% gross IRR and a 2x money multiple, demonstrating the success of its minority investment thesis.
A core element of BGF's national platform is its strong regional focus, with 74% of its capital invested outside of London and the South East. This commitment is supported by a network of 15 offices across the UK and Ireland, ensuring access to capital for promising businesses nationwide. This widespread presence has been instrumental in building a broad and diversified portfolio.
Recent Milestones and Portfolio Success
The £5 billion threshold was crossed with BGF's third investment in Gaussion, a company pioneering battery intelligence technology. This particular deal highlights BGF's focus on backing innovative businesses in sectors critical to future economic growth. Gaussion's technology, which improves battery performance and lifespan, has wide-ranging applications from electric vehicles to data centres.
BGF's recent activity also includes investments in neurodegenerative disease drug developer TRIMTECH Therapeutics and public-sector software provider Fivium. Furthermore, the firm's ability to scale companies is exemplified by the successful exit of OrganOx at a $1.5 billion valuation, one of the UK's largest medtech exits. This track record has led to BGF being recognised as the most active investor in the UK's fastest-growing private equity-backed companies.
Leadership Perspective on the Milestone
Andy Gregory, Chief Executive Officer of BGF, commented that the deployment of £5 billion reflects the size of the market opportunity the firm was created to address. He emphasized that the minority investment model allows BGF to partner with entrepreneurs on their own terms, delivering real economic impact. Gregory reaffirmed the firm's ongoing commitment to backing ambitious businesses across the UK and Ireland.
Chief Investment Officer Ben Barker described reaching the milestone as a significant achievement for the firm. He noted that BGF has built a diversified portfolio with performance reflected in strong realisations, allowing capital to be recycled into new opportunities. Barker highlighted the strong pipeline for future investments and exits, positioning BGF to build on its successful track record.
Looking ahead, BGF has committed to investing a further £3 billion over the next five years, signalling its confidence in the continued opportunities within the UK and Irish markets. This new commitment solidifies BGF's position as one of the most active and influential growth investors in the region. The firm is well-placed to continue empowering the next generation of scale-up businesses and driving economic prosperity.